These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 17923246

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Macrophage 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in sitosterolemia: effects of increased cellular cholesterol and sitosterol concentrations.
    Nguyen LB, Salen G, Shefer S, Tint GS, Ruiz F.
    Metabolism; 2001 Oct; 50(10):1224-9. PubMed ID: 11586498
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 6. Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatin.
    Suárez Y, Fernández C, Gómez-Coronado D, Ferruelo AJ, Dávalos A, Martínez-Botas J, Lasunción MA.
    Cardiovasc Res; 2004 Nov 01; 64(2):346-55. PubMed ID: 15485695
    [Abstract] [Full Text] [Related]

  • 7. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase activity is inhibited by cholesterol and up-regulated by sitosterol in sitosterolemic fibroblasts.
    Honda A, Salen G, Honda M, Batta AK, Tint GS, Xu G, Chen TS, Tanaka N, Shefer S.
    J Lab Clin Med; 2000 Feb 01; 135(2):174-9. PubMed ID: 10695663
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
    McAnally JA, Gupta J, Sodhani S, Bravo L, Mo H.
    Exp Biol Med (Maywood); 2007 Apr 01; 232(4):523-31. PubMed ID: 17392488
    [Abstract] [Full Text] [Related]

  • 11. Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells.
    Yamasaki D, Nakamura T, Okamura N, Kokudai M, Inui N, Takeuchi K, Watanabe H, Hirai M, Okumura K, Sakaeda T.
    Eur J Pharm Sci; 2009 May 12; 37(2):126-32. PubMed ID: 19429419
    [Abstract] [Full Text] [Related]

  • 12. Reversal of P-glycoprotein-mediated multidrug resistance by cholesterol derived from low density lipoprotein in a vinblastine-resistant human lymphoblastic leukemia cell line.
    Shu Y, Liu H.
    Biochem Cell Biol; 2007 Oct 12; 85(5):638-46. PubMed ID: 17901905
    [Abstract] [Full Text] [Related]

  • 13. Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation.
    Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A.
    Anticancer Res; 2001 Oct 12; 21(2A):847-56. PubMed ID: 11396174
    [Abstract] [Full Text] [Related]

  • 14. Interaction of the HMG-CoA reductase inhibitor lovastatin and nitric oxide in cardiomyocyte cell death.
    Rabkin SW, Tsang MY.
    Pharmacology; 2008 Oct 12; 82(1):74-82. PubMed ID: 18504415
    [Abstract] [Full Text] [Related]

  • 15. Lovastatin inhibits oxidized low-density lipoprotein-induced plasminogen activator inhibitor and transforming growth factor-beta1 expression via a decrease in Ras/extracellular signal-regulated kinase activity in mesangial cells.
    Song CY, Kim BC, Lee HS.
    Transl Res; 2008 Jan 12; 151(1):27-35. PubMed ID: 18061125
    [Abstract] [Full Text] [Related]

  • 16. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin.
    Massy ZA, Kim Y, Guijarro C, Kasiske BL, Keane WF, O'Donnell MP.
    Biochem Biophys Res Commun; 2000 Jan 19; 267(2):536-40. PubMed ID: 10631097
    [Abstract] [Full Text] [Related]

  • 17. High-dose lovastatin decreased basal prostacyclin production in cultured endothelial cells.
    Zhou Q, Zhou Y, Kummerow FA.
    Prostaglandins Other Lipid Mediat; 2009 Jun 19; 89(1-2):1-7. PubMed ID: 19135546
    [Abstract] [Full Text] [Related]

  • 18. Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line.
    Romiti N, Tramonti G, Chieli E.
    Toxicol Appl Pharmacol; 2002 Sep 01; 183(2):83-91. PubMed ID: 12387747
    [Abstract] [Full Text] [Related]

  • 19. Decreased ABCB1 mRNA expression induced by atorvastatin results from enhanced mRNA degradation in HepG2 cells.
    Rodrigues AC, Curi R, Hirata MH, Hirata RD.
    Eur J Pharm Sci; 2009 Jun 28; 37(3-4):486-91. PubMed ID: 19394420
    [Abstract] [Full Text] [Related]

  • 20. [HMG-CoA reductase inhibitor for therapy of patients with hyperlipoproteinemia ].
    Jingami H.
    Nihon Rinsho; 1994 Dec 28; 52(12):3271-8. PubMed ID: 7853722
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.